title: Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry work-up.
abstract: Introduction: While multidimensional flow cytometry (MDF) has great utility in diagnostic work-ups of patients with suspected myelodysplastic syndromes (MDS), only the myeloid lineage has demonstrated reproducible abnormalities from multiple laboratories. With the effects of ammonium chloride (NH4Cl) lysis on erythroid progenitors previously described, we applied this protocol to a patient cohort with diagnosed MDS to investigate phenotypic abnormalities that indicate erythroid dysplasia. Method: Bone marrow specimens [39 MDS, 9 acute myeloid leukemia (AML), 7 JAK2V617Fpositive myeloproliferative neoplasms (MPN), 5 nutritional deficiencies] were processed by NH4Cl lysis and Ficoll preparation and evaluated by MDF using a difference from normal algorithm. Results: For the MDS cohort, phenotypic abnormalities on the mature erythroid progenitors were frequent for CD71 and CD36 (36% for each antigen); abnormalities for CD235a (8%) were observed. Among immature erythroid progenitors, abnormal maturation patterns (≤5%) and increased CD105 intensity (9%) were seen. Increased frequency of CD105 bright cells was observed (18%). While antigenic abnormalities correlated between NH4Cl lysis and Ficoll preparation, the lysis method demonstrated the most consistent quantitative antigen intensities. Mean erythroid phenotypic abnormalities and prognostic cytogenetic subgroups correlated strongly. Morphologic and erythroid phenotypic abnormalities correlated, as did increasing FCSS and number of erythroid abnormalities, albeit without further increase for AML patients. Discussion: These data expand the understanding of erythropoiesis and define immunophenotypic abnormalities that indicate dyserythropoiesis in MDS utilizing a lysis protocol practical for routine implementation in clinical flow cytometric work-up. Preliminary studies also indicate strong correlation between phenotypic erythroid dysplasia and poor prognosis, as classified cytogenetically. © 2014 Clinical Cytometry Society.
authors.affiliation: HematoLogics, Inc., Seattle, WA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Eidenschink Brodersen
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Menssen
authors.forename: Jamie R
authors.initials: JR
authors.lastname: Wangen
authors.forename: Christine F
authors.initials: CF
authors.lastname: Stephenson
authors.forename: Monica E
authors.initials: ME
authors.lastname: de Baca
authors.forename: Barbara K
authors.initials: BK
authors.lastname: Zehentner
authors.forename: Denise A
authors.initials: DA
authors.lastname: Wells
authors.forename: Michael R
authors.initials: MR
authors.lastname: Loken
keywords: TP53; ammonium chloride lysis; dyserythropoiesis; erythroid dysplasia; erythroleukemia; flow cytometry; myelodysplastic syndrome